Treatment | Joints with erosions |
---|---|
Suboptimal anti-TNF (50 μg) | |
anti-CD4 alone | 13/18 (72%) |
anti-TNF alone | 14/19 (74%) |
anti-CD4/anti-TNF | 4/18 (22%)2-150 |
control mAb | 17/18 (94%) |
Optimal anti-TNF (300 μg) | |
anti-CD4 alone | 10/12 (83%) |
anti-TNF alone | 6/11 (54%)2-151 |
anti-CD4/anti-TNF | 4/13 (31%)2-152 |
control mAb | 12/12 (100%) |